Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anixa Biosciences Inc ANIX

Healthcare Biotechnology
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well... see more

Recent & Breaking News (NDAQ:ANIX)

Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic

PR Newswire October 26, 2022

Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

PR Newswire October 10, 2022

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium

PR Newswire September 12, 2022

Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PR Newswire August 31, 2022

Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial

PR Newswire August 15, 2022

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology

PR Newswire July 21, 2022

Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology

PR Newswire June 21, 2022

Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference

PR Newswire May 5, 2022

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire April 28, 2022

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022

PR Newswire April 6, 2022

Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

PR Newswire March 30, 2022

Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC

PR Newswire March 17, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

PR Newswire January 25, 2022

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

PR Newswire January 24, 2022

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

PR Newswire December 16, 2021

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

PR Newswire December 7, 2021

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

PR Newswire October 26, 2021

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

PR Newswire October 6, 2021

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

PR Newswire October 1, 2021

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

PR Newswire September 14, 2021